4 billion market!

On October 19th, the results of the planned selection of the second batch of medicines in Shandong Province (Lu-Jin Alliance) for centralized and large-volume procurement were announced
.
919 products from 284 companies were declared, and the final 50 drugs produced the results of the proposed selection, with an average price reduction of 45.
81% and a maximum reduction of 92.
74%
.
This collection incorporates drugs that are reported by the masses of high prices, large amounts of medical institutions, and a wide range of patient audiences .
It covers clinical subjects such as cardiovascular, cerebrovascular, nerve, respiration, digestion, anti-tumor, hematology and surgery, covering Shandong and Shanxi.
The provincial drug sales market has reached 3.
925 billion yuan
.
Judging from the spread of price cuts, Dandong Medichuang Pharmaceutical’s sodium ozagrel for injection has dropped from 16.
52 yuan/branch to 1.
2 yuan/branch, a decrease of 92.
74%
.
This product is an antiplatelet drug, which can treat thrombotic diseases and prevent thrombosis
.
According to data from Minai.
com, in 2021, the market of Ozagrel Sodium Injection in Shandong and Shanxi will be dominated by Dandong Yichuang Pharmaceutical, with a market share of more than 40%
.
 　　The largest price reduction is the terlipressin for injection selected by Tianma Tianji Biology.
The price has been reduced from 315.
8 yuan/piece to 37.
8 yuan/piece, and the single price is reduced by 278 yuan
.
According to data from Menet.
com, in 2021, terlipressin injection will be dominated by Shenzhen Hanyu Pharmaceutical in the markets of Shandong and Shanxi in public hospitals in key provinces and cities in H1
.
 　　Shanghai Biochemical Pharmaceutical drug and Shanghai Hefeng Pharmaceutical injection of oxytocin, both as a shortage of medicine and finalists, and offer the same price, fell to 0; shortage of drugs are also several non- enterprise products 0 price finalists, including Changchun Kinsey Pharmaceutical triptorelin acetate injection, Beijing Hokuriku Gd-DTPA injection and so on
.
 　　According to data from Meinnet.
com, in 2021 H1 key provinces and municipalities in public hospitals , the market for oxytocin injection in Shandong and Shanxi will be dominated by Nanjing Xinbai Pharmaceutical.
The proposed Shanghai Shangyao No.
1 Biochemical Pharmaceutical and Shanghai Hefeng Pharmaceutical will be selected.
The market share is not high; the market for gadopentetate meglumine injection is dominated by the original research manufacturer.
The three domestic companies are planning to be selected this time, and the process of copying and replacing the original research is accelerated
.
 　　Lu-Jin inter-provincial alliance drug centralized procurement quotation products proposed results　　Source: Mi Neiwang database, Shandong Public Resources Trading Center, etc.
 　　Note: The chemical drug terminal competition pattern database of public hospitals in key provinces and cities is based on the chemical drug procurement data of nearly 700 sample provincial and municipal public hospitals in 20+ provinces and cities, and the sample provincial and municipal sample hospitals that continuously monitor the entire category of chemical drugs Database
.
The data covers 14 categories, 90 subcategories, and a total of 4800+ generic name varieties, which can analyze the drug use structure of medical institutions from multiple angles and dimensions
.
This data is updated quarterly to provide timely feedback on the impact of policy changes on products, and analyze the sales, market shares, sales trends and development laws of various categories and varieties of chemical drugs in 20+ provinces and cities in all categories in an all-round and multi-dimensional manner
.
　　On October 19th, the results of the planned selection of the second batch of medicines in Shandong Province (Lu-Jin Alliance) for centralized and large-volume procurement were announced
.
919 products from 284 companies were declared, and the final 50 drugs produced the results of the proposed selection, with an average price reduction of 45.
81% and a maximum reduction of 92.
74%
.
 　　This collection incorporates drugs that are reported by the masses of high prices, large amounts of medical institutions, and a wide range of patient audiences .
It covers clinical subjects such as cardiovascular, cerebrovascular, nerve, respiration, digestion, anti-tumor, hematology and surgery, covering Shandong and Shanxi.
The provincial drug sales market has reached 3.
925 billion yuan
.
 　　Judging from the spread of price cuts, Dandong Medichuang Pharmaceutical’s sodium ozagrel for injection has dropped from 16.
52 yuan/branch to 1.
2 yuan/branch, a decrease of 92.
74%
.
This product is an antiplatelet drug, which can treat thrombotic diseases and prevent thrombosis
.
According to data from Minai.
com, in 2021, the market of Ozagrel Sodium Injection in Shandong and Shanxi will be dominated by Dandong Yichuang Pharmaceutical, with a market share of more than 40%
.
 　　The largest price reduction is the terlipressin for injection selected by Tianma Tianji Biology.
The price has been reduced from 315.
8 yuan/piece to 37.
8 yuan/piece, and the single price is reduced by 278 yuan
.
According to data from Menet.
com, in 2021, terlipressin injection will be dominated by Shenzhen Hanyu Pharmaceutical in the markets of Shandong and Shanxi in public hospitals in key provinces and cities in H1
.
 　　Shanghai Biochemical Pharmaceutical drug and Shanghai Hefeng Pharmaceutical injection of oxytocin, both as a shortage of medicine and finalists, and offer the same price, fell to 0; shortage of drugs are also several non- enterprise products 0 price finalists, including Changchun Kinsey Pharmaceutical triptorelin acetate injection, Beijing Hokuriku Gd-DTPA injection and so on
.
 　　According to data from Meinnet.
com, in 2021 H1 key provinces and municipalities in public hospitals , the market for oxytocin injection in Shandong and Shanxi will be dominated by Nanjing Xinbai Pharmaceutical.
The proposed Shanghai Shangyao No.
1 Biochemical Pharmaceutical and Shanghai Hefeng Pharmaceutical will be selected.
The market share is not high; the market for gadopentetate meglumine injection is dominated by the original research manufacturer.
The three domestic companies are planning to be selected this time, and the process of copying and replacing the original research is accelerated
.
 　　Lu-Jin inter-provincial alliance drug centralized procurement quotation products proposed results　　Source: Mi Neiwang database, Shandong Public Resources Trading Center, etc.
 　　Note: The chemical drug terminal competition pattern database of public hospitals in key provinces and cities is based on the chemical drug procurement data of nearly 700 sample provincial and municipal public hospitals in 20+ provinces and cities, and the sample provincial and municipal sample hospitals that continuously monitor the entire category of chemical drugs Database
.
The data covers 14 categories, 90 subcategories, and a total of 4800+ generic name varieties, which can analyze the drug use structure of medical institutions from multiple angles and dimensions
.
This data is updated quarterly to provide timely feedback on the impact of policy changes on products, and analyze the sales, market shares, sales trends and development laws of various categories and varieties of chemical drugs in 20+ provinces and cities in all categories in an all-round and multi-dimensional manner
.
　　On October 19th, the results of the planned selection of the second batch of medicines in Shandong Province (Lu-Jin Alliance) for centralized and large-volume procurement were announced
.
919 products from 284 companies were declared, and the final 50 drugs produced the results of the proposed selection, with an average price reduction of 45.
81% and a maximum reduction of 92.
74%
.
 　　This collection incorporates drugs that are reported by the masses of high prices, large amounts of medical institutions, and a wide range of patient audiences .
It covers clinical subjects such as cardiovascular, cerebrovascular, nerve, respiration, digestion, anti-tumor, hematology and surgery, covering Shandong and Shanxi.
The provincial drug sales market has reached 3.
925 billion yuan
.
Medicine medicine 　　Judging from the spread of price cuts, Dandong Medichuang Pharmaceutical’s sodium ozagrel for injection has dropped from 16.
52 yuan/branch to 1.
2 yuan/branch, a decrease of 92.
74%
.
This product is an antiplatelet drug, which can treat thrombotic diseases and prevent thrombosis
.
According to data from Minai.
com, in 2021, the market of Ozagrel Sodium Injection in Shandong and Shanxi will be dominated by Dandong Yichuang Pharmaceutical, with a market share of more than 40%
.
Disease disease 　　The largest price reduction is the terlipressin for injection selected by Tianma Tianji Biology.
The price has been reduced from 315.
8 yuan/piece to 37.
8 yuan/piece, and the single price is reduced by 278 yuan
.
According to data from Menet.
com, in 2021, terlipressin injection will be dominated by Shenzhen Hanyu Pharmaceutical in the markets of Shandong and Shanxi in public hospitals in key provinces and cities in H1
.
 　　Shanghai Biochemical Pharmaceutical drug and Shanghai Hefeng Pharmaceutical injection of oxytocin, both as a shortage of medicine and finalists, and offer the same price, fell to 0; shortage of drugs are also several non- enterprise products 0 price finalists, including Changchun Kinsey Pharmaceutical triptorelin acetate injection, Beijing Hokuriku Gd-DTPA injection and so on
.
Business enterprise 　　According to data from Meinnet.
com, in 2021 H1 key provinces and municipalities in public hospitals , the market for oxytocin injection in Shandong and Shanxi will be dominated by Nanjing Xinbai Pharmaceutical.
The proposed Shanghai Shangyao No.
1 Biochemical Pharmaceutical and Shanghai Hefeng Pharmaceutical will be selected.
The market share is not high; the market for gadopentetate meglumine injection is dominated by the original research manufacturer.
The three domestic companies are planning to be selected this time, and the process of copying and replacing the original research is accelerated
.
Hospital hospital 　　Lu-Jin inter-provincial alliance drug centralized procurement quotation products proposed results　　　Source: Mi Neiwang database, Shandong Public Resources Trading Center, etc.
 　　Note: The chemical drug terminal competition pattern database of public hospitals in key provinces and cities is based on the chemical drug procurement data of nearly 700 sample provincial and municipal public hospitals in 20+ provinces and cities, and the sample provincial and municipal sample hospitals that continuously monitor the entire category of chemical drugs Database
.
The data covers 14 categories, 90 subcategories, and a total of 4800+ generic name varieties, which can analyze the drug use structure of medical institutions from multiple angles and dimensions
.
This data is updated quarterly to provide timely feedback on the impact of policy changes on products, and analyze the sales, market shares, sales trends and development laws of various categories and varieties of chemical drugs in 20+ provinces and cities in all categories in an all-round and multi-dimensional manner
.
Purchasing Procurement